Journal of International Oncology››2017,Vol. 44››Issue (11): 864-865.doi:10.3760/cma.j.issn.1673-422X.2017.11.015

Previous ArticlesNext Articles

Bevacizumab in the treatment of non-small-cell lung cancer with brain metastases

Liu Mengshi, Yang Haiyan, Li Hongmei

  1. Department of Oncology, Affiliated Hospital of Qingdao University, Qingdao 266000, China
  • Received:2017-09-11Online:2017-11-08Published:2017-11-24
  • Contact:Liu Mengshi E-mail:obstriker@163.com

Abstract:The occurrence of brain metastases in lung cancer affects the prognosis of patients. Following surgery, whole brain radiotherapy, stereotactic radiotherapy and chemotherapy, antiangiogenesis therapy has become a new treatment option for lung cancer patients with brain metastases. As an antiangiogenic drug, bevacizumab has a better effect of controlling peritumoral edema. Studies have shown that bevacizumab combined with chemotherapy, radiotherapy to treat nonsmall cell lung cancer with brain metastasis has a good efficacy and safety.

Key words:Carcinoma, non-small cell lung,Neoplasm metastases,Bevacizumab